BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

334 related articles for article (PubMed ID: 35348553)

  • 1. Comparison tables: H2-receptor antagonists and PPIs.
    Med Lett Drugs Ther; 2022 Apr; 64(1647):e56-e57. PubMed ID: 35348553
    [No Abstract]   [Full Text] [Related]  

  • 2. Drugs for GERD and peptic ulcer disease.
    Med Lett Drugs Ther; 2022 Apr; 64(1647):49-56. PubMed ID: 35348552
    [No Abstract]   [Full Text] [Related]  

  • 3. An overview of proton pump inhibitors.
    Der G
    Gastroenterol Nurs; 2003; 26(5):182-90. PubMed ID: 14603076
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Addendum: Dexlansoprazole for GERD.
    Med Lett Drugs Ther; 2022 May; 64(1650):79-80. PubMed ID: 35536912
    [No Abstract]   [Full Text] [Related]  

  • 5. [Safety of proton pump inhibitors].
    Esplugues JV; Martí-Cabrera M; Ponce J
    Med Clin (Barc); 2006 Nov; 127(20):790-5. PubMed ID: 17198667
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adverse effects reported in the use of gastroesophageal reflux disease treatments in children: a 10 years literature review.
    Cohen S; Bueno de Mesquita M; Mimouni FB
    Br J Clin Pharmacol; 2015 Aug; 80(2):200-8. PubMed ID: 25752807
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetic optimisation in the treatment of gastro-oesophageal reflux disease.
    Hatlebakk JG; Berstad A
    Clin Pharmacokinet; 1996 Nov; 31(5):386-406. PubMed ID: 9118586
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Healing and relapse rates in gastroesophageal reflux disease treated with the newer proton-pump inhibitors lansoprazole, rabeprazole, and pantoprazole compared with omeprazole, ranitidine, and placebo: evidence from randomized clinical trials.
    Caro JJ; Salas M; Ward A
    Clin Ther; 2001 Jul; 23(7):998-1017. PubMed ID: 11519776
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities.
    Li XQ; Andersson TB; Ahlström M; Weidolf L
    Drug Metab Dispos; 2004 Aug; 32(8):821-7. PubMed ID: 15258107
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [New-generation proton pump inhibitors: progress in the treatment of peptic acid diseases?].
    de Korwin JD; Ducrotté P; Vallot T
    Presse Med; 2004 Jun; 33(11):746-54. PubMed ID: 15257232
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of Antioxidant Effects of the Proton Pump-Inhibiting Drugs Omeprazole, Esomeprazole, Lansoprazole, Pantoprazole, and Rabeprazole.
    Abed MN; Alassaf FA; Jasim MHM; Alfahad M; Qazzaz ME
    Pharmacology; 2020; 105(11-12):645-651. PubMed ID: 32289807
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro inhibition of methadone and oxycodone cytochrome P450-dependent metabolism: reversible inhibition by H2-receptor agonists and proton-pump inhibitors.
    Moody DE; Liu F; Fang WB
    J Anal Toxicol; 2013 Oct; 37(8):476-85. PubMed ID: 23857299
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical impact of CYP2C19 polymorphism on the action of proton pump inhibitors: a review of a special problem.
    Klotz U
    Int J Clin Pharmacol Ther; 2006 Jul; 44(7):297-302. PubMed ID: 16961157
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vonoprazan (Voquezna) for erosive esophagitis.
    Med Lett Drugs Ther; 2023 Dec; 65(1692):203-205. PubMed ID: 38133593
    [No Abstract]   [Full Text] [Related]  

  • 15. Meta-analysis: proton pump inhibitor or H2-receptor antagonist for Helicobacter pylori eradication.
    Graham DY; Hammoud F; El-Zimaity HM; Kim JG; Osato MS; El-Serag HB
    Aliment Pharmacol Ther; 2003 May; 17(10):1229-36. PubMed ID: 12755836
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of six proton pump inhibitors as inhibitors of various human cytochromes P450: focus on cytochrome P450 2C19.
    Zvyaga T; Chang SY; Chen C; Yang Z; Vuppugalla R; Hurley J; Thorndike D; Wagner A; Chimalakonda A; Rodrigues AD
    Drug Metab Dispos; 2012 Sep; 40(9):1698-711. PubMed ID: 22648560
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The efficacy and safety of proton pump inhibitors vs histamine-2 receptor antagonists for stress ulcer bleeding prophylaxis among critical care patients: a meta-analysis.
    Lin PC; Chang CH; Hsu PI; Tseng PL; Huang YB
    Crit Care Med; 2010 Apr; 38(4):1197-205. PubMed ID: 20173630
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Proton pump inhibitors versus H2-antagonists: a meta-analysis of their efficacy in treating bleeding peptic ulcer.
    Gisbert JP; González L; Calvet X; Roqué M; Gabriel R; Pajares JM
    Aliment Pharmacol Ther; 2001 Jul; 15(7):917-26. PubMed ID: 11421865
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Are proton pump inhibitors the first choice for acute treatment of gastric ulcers? A meta analysis of randomized clinical trials.
    Salas M; Ward A; Caro J
    BMC Gastroenterol; 2002 Jul; 2():17. PubMed ID: 12119060
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 17.